Exelixis (EXEL) Change in Cash (2010 - 2026)
Exelixis (EXEL) posted quarterly Change in Cash of -$256.3 million for Q2 2026, down 662.41% year-over-year from $45.6 million in Q2 2025, and down 341.4% quarter-over-quarter from $106.2 million in Q1 2026.
Analysis
Exelixis (EXEL) Change in Cash (2010 - 2026) Analysis & Trends
Exelixis' Change in Cash history runs 17 years deep, the most recent figure standing at -$256.3 million for Q2 2026.
- In Q2 2026, Change in Cash fell 662.41% year-over-year to -$256.3 million; the TTM figure through Apr 2026 stood at $42.4 million (up 155.93% YoY), while the FY2026 annual figure was $265.1 million, up 681.14% from the prior year.
- Change in Cash for Q2 2026 stood at -$256.3 million, down from $106.2 million in the prior quarter.
- The five-year high for Change in Cash was $211.9 million in Q4 2025, with the low at -$256.3 million in Q2 2026.
- The 5-year median for Change in Cash is -$33.6 million (2025), against an average of -$25.7 million.
- The sharpest annual moves came in 2025 and 2026: Change in Cash plunged 879.38% in 2025, then soared 359.17% in 2026.
- Exelixis' Change in Cash stood at -$174.1 million in 2022, then grew by 23.11% to -$133.9 million in 2023, then jumped by 144.74% to $59.9 million in 2024, then soared by 253.78% to $211.9 million in 2025, then plunged by 220.99% to -$256.3 million in 2026.
- Business Quant data shows EXEL's Change in Cash at -$256.3 million in Q2 2026, $106.2 million in Q1 2026, and $211.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 55.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 55.30 Mn |
| Apr 3, 2026 | -256.34 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Dec 29, 2023 | -133.87 Mn |
| Sep 29, 2023 | -67.62 Mn |
| Jun 30, 2023 | -77.60 Mn |
| Mar 31, 2023 | 39.40 Mn |
| Dec 30, 2022 | -174.09 Mn |
| Sep 30, 2022 | 39.08 Mn |
| Jul 1, 2022 | -99.59 Mn |
| Apr 1, 2022 | 73.39 Mn |
| Dec 31, 2021 | 65.40 Mn |
| Oct 1, 2021 | 59.19 Mn |